According to the recent study the pharmaceutical contract manufacturing market is projected to reach an estimated $222.0 billion by 2028 from $156.0 billion in 2023, at a CAGR of 7.3% from 2023 to 2028. Growth in this market is primarily driven by growing demand for generic and specialty medicines, increasing investments in pharmaceutical RD activities, and rising trend for CMOs (contract manufacturing organization) for "one-stop-shop" benefit.

A more than 150 – page report is developed to understand trends, opportunities and forecast in pharmaceutical contract manufacturing market by services (manufacturing [API, FDF (parenteral, injectable, tablet, capsule, and oral liquid)], drug development, and biologics manufacturing), end use industry (big pharmaceutical, small medium-sized pharmaceutical, and generic pharmaceutical), and region (North America, Europe, Asia Pacific, and the Rest of the World).

Download sample report by clicking on below link https://www.lucintel.com/pharmaceutical-contract-manufacturing-market.aspx

“Biologics manufacturing market is expected to remain the largest segment during the forecast period.”

Based on services, the pharmaceutical contract manufacturing market is segmented into manufacturing [API, FDF (parenteral, injectable, tablet, capsule, and oral liquid)], drug development, and biologics manufacturing. Lucintel forecasts that the biologics manufacturing market is expected to remain the largest segment due to increasing need for producing vaccines and biosimilars.

“Within the pharmaceutical contract manufacturing market, the big pharmaceutical segment is expected to remain the largest end use industry”

Based on end use industry the big pharmaceutical segment is expected to witness the highest growth over the forecast period due to growing trend among large pharmacies to contract out pharmaceutical production in order to minimize the pricing pressure and pipeline issues in their operations along with increasing demand for optimization of execution costs as bestselling medication patents expires.

“Asia pacific will dominate the pharmaceutical contract manufacturing market in near future”

APAC is expected to remain the largest region due to increasing demand from geriatric population, growing outsourcing activities and expansion of manufacturing capabilities of the local key players in the region.

Download Brochure of this report by clicking on https://www.lucintel.com/pharmaceutical-contract-manufacturing-market.aspx

Major players of pharmaceutical contract manufacturing market are adopting various growth strategies like new product launches, expansions, merger and acquisitions, partnerships, agreements, and collaborations to expand their presence in this market. Thermo Fisher Scientific, Catalent, Lonza, Almac Group, Recipharm, Patheon, Grifols International, Dalton Pharma Services, and AbbVie are among the major pharmaceutical contract manufacturing providers.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link https://www.lucintel.com/pharmaceutical-contract-manufacturing-market.aspx or helpdesk@lucintel.com